Matthew Ong spoke with Richard Goldberg.
Matthew Ong spoke with John Stewart.
The Oregon Health Authority is weighing a recommendation to deny Medicaid coverage for next-generation sequencing tests in the state.
Historically, oncology drug development has evolved on what may seem to be a different planet, at least relative to mainstream clinical pharmacology.
FDA has approved AstraZeneca's moxetumomab pasudotox-tdfk, a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Boehringer Ingelheim has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies.
Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Crown Bioscience has completed a joint study with CARsgen Therapeutics and Shanghai Cancer Institute, demonstrating the elimination of gastric tumors in mice using CLDN18.2 targeting CAR-T cells. The work was recently published in the Journal of the National Cancer Institute.
Merck KGaA and Pfizer Inc. announced positive top-line results from the pivotal phase III JAVELIN Renal 101 study evaluating Bavencio (avelumab) in combination with Inlyta (axitinib), compared with Sutent (sunitinib) as initial therapy for patients with advanced renal cell carcinoma.
IMV Inc. said it has expanded its clinical program with a phase II basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with select advanced or recurrent solid tumors.
